Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07941258
NA

Dexmedetomidine for Preventing Postoperative Delirium and a Risk Prediction Nomogram in Older Adults Undergoing Gastrointestinal Surgery

Sponsor: Hanoi Medical University

View on ClinicalTrials.gov

Summary

Postoperative delirium (POD) is a common and serious complication in older adults after major gastrointestinal surgery and is associated with longer hospital stay, long-term cognitive decline and higher mortality. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist with sedative, anti-inflammatory and opioid-sparing effects, may reduce POD, but evidence in older patients undergoing gastrointestinal surgery remains inconsistent, and tools to identify which patients are at highest risk are lacking. The goal of this randomized, double-blind, placebo-controlled trial is to learn whether intraoperative and early postoperative dexmedetomidine prevents POD in patients aged 60 years or older undergoing elective gastrointestinal surgery under general anesthesia, and to develop a risk prediction nomogram for POD in this population. The main questions it aims to answer are: 1. Does dexmedetomidine lower the incidence of POD within 5 days after surgery compared with placebo, and is it safe? 2. How accurately can a prediction model (nomogram) built from preoperative and intraoperative factors estimate each patient's risk of POD? Researchers will also examine how dexmedetomidine changes postoperative inflammatory and stress markers (IL-6, cortisol, CRP, NLR, SII) and their association with POD, and whether the benefit of dexmedetomidine differs across baseline-risk strata. Participants will be randomly assigned to dexmedetomidine or placebo (0.9% saline). The blinded infusion starts 15 minutes before induction of anesthesia (dexmedetomidine 0.5 mcg/kg over 15 minutes, then 0.5 mcg/kg/h until 2 hours after surgery, or the same volume and rate of saline). Delirium will be assessed three times daily with the 3D-CAM (or CAM-ICU for patients who cannot be interviewed) from the end of surgery until postoperative day 5 or hospital discharge.

Official title: Efficacy of Dexmedetomidine in Preventing Postoperative Delirium and a Risk Prediction Nomogram in Geriatric Patients Undergoing Gastrointestinal Surgery: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial

Key Details

Gender

All

Age Range

60 Years - Any

Study Type

INTERVENTIONAL

Enrollment

630

Start Date

2026-12-01

Completion Date

2028-04-30

Last Updated

2026-11-19

Healthy Volunteers

No

Interventions

DRUG

Dexmedetomidine

Selective alpha-2 adrenergic agonist. Dexmedetomidine Invagen 200 mcg/2 mL (SIA Pharmidea, Latvia; Vietnamese marketing authorization 475114010723). Dose reduced to 0.3 mcg/kg/h for bradycardia with hypotension; stopped for HR \< 40/min, new 2nd-3rd degree AV block, refractory hypotension, or RASS \<= -3 / SpO2 \< 90% after extubation.

DRUG

Placebo

Identical-appearing 0.9% sodium chloride solution administered with the same syringe, label, volume, rate and duration.

Locations (1)

Hanoi Medical University Hospital

Hanoi, Vietnam